Bad Blood: Secrets and Lies in a Silicon Valley Startup
"In 2014 Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup 'unicorn' promised to revolutionize the medical industry with a machine that would make blood tests significantly faster and easier. . . There was just one problem: The technology didn't work.
| Quantity | Price | Discount |
|---|---|---|
| List Price | $30.00 |
Non-returnable discount pricing
$30.00
Book Information
| Publisher: | Knopf Publishing Group |
|---|---|
| Publish Date: | 05/21/2018 |
| Pages: | 352 |
| ISBN-13: | 9781524731656 |
| ISBN-10: | 152473165X |
| Language: | Eng |
What We're Saying
Bad Blood has been named the Financial Times and McKinsey Business Book of the Year. READ FULL DESCRIPTION
Six finalists for the FT/McKinsey Business Book of the Year have been announced. READ FULL DESCRIPTION
John Carreyrou's new book is in part a story about truly atrocious leadership and management, and a powerful reminder of the importance and power of a free press. READ FULL DESCRIPTION
In order of their release dates, these are just some of the books we're hoping to get to know better in May. READ FULL DESCRIPTION
Full Description
NATIONAL BESTSELLER - The gripping story of Elizabeth Holmes and Theranos--one of the biggest corporate frauds in history--a tale of ambition and hubris set amid the bold promises of Silicon Valley, rigorously reported by the prize-winning journalist. With a new Afterword. "Chilling ... Reads like a thriller ... Carreyrou tells [the Theranos story] virtually to perfection." --The New York Times Book Review
In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the next Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with its breakthrough device, which performed the whole range of laboratory tests from a single drop of blood. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at more than $9 billion, putting Holmes's worth at an estimated $4.5 billion. There was just one problem: The technology didn't work. Erroneous results put patients in danger, leading to misdiagnoses and unnecessary treatments. All the while, Holmes and her partner, Sunny Balwani, worked to silence anyone who voiced misgivings--from journalists to their own employees.
In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the next Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with its breakthrough device, which performed the whole range of laboratory tests from a single drop of blood. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at more than $9 billion, putting Holmes's worth at an estimated $4.5 billion. There was just one problem: The technology didn't work. Erroneous results put patients in danger, leading to misdiagnoses and unnecessary treatments. All the while, Holmes and her partner, Sunny Balwani, worked to silence anyone who voiced misgivings--from journalists to their own employees.
